BiotechTube
HepQuant

HepQuant

Denver, United States· Est.
hepquant.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5.5M

Overview

HepQuant is a commercial-stage diagnostics company focused on transforming the management of liver disease through its proprietary, noninvasive blood test, HepQuant DuO. The test quantitatively measures liver function and portal blood flow, providing a Disease Severity Index to help clinicians stratify risk and manage patients with chronic liver conditions like cirrhosis and MASH. The company operates a CLIA lab, markets its test as a Laboratory Developed Test (LDT), and is also targeting the pharmaceutical sector for use in clinical trials. With a large addressable market of over 100 million Americans with some form of liver disease, HepQuant aims to become a standard tool in hepatology.

Liver DiseaseCirrhosisMASH (Metabolic dysfunction-associated steatohepatitis)Portal Hypertension

Technology Platform

Proprietary dual-cholate, blood-based test that quantitatively measures hepatic function and portal-systemic shunting to generate a Disease Severity Index (DSI).

Funding History

2
Total raised:$5.5M
Series A$5M
Grant$500K

Opportunities

The massive and growing prevalence of liver disease, particularly MASH, creates a urgent need for better quantitative monitoring tools.
HepQuant's unique functional assessment can differentiate it in both clinical management and as a valuable biomarker for the booming liver drug development sector.

Risk Factors

Key risks include reliance on the LDT business model with its associated reimbursement challenges, the difficulty of driving adoption in a competitive diagnostic market, and the potential for competing technologies to emerge.

Competitive Landscape

HepQuant competes with other non-invasive liver diagnostic tools, including transient elastography (e.g., FibroScan), serum biomarker panels (e.g., ELF, FibroTest), and imaging-based techniques. Its differentiation lies in measuring dynamic liver function and portal blood flow, rather than just fibrosis or stiffness.

More companies in Diagnostics & Precision Medicine →More companies in United States →